Callan Family Office LLC Purchases 117,174 Shares of Elanco Animal Health Incorporated $ELAN

Callan Family Office LLC grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 239.0% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 166,198 shares of the company’s stock after buying an additional 117,174 shares during the quarter. Callan Family Office LLC’s holdings in Elanco Animal Health were worth $2,373,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Allworth Financial LP grew its stake in Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares during the last quarter. Wealthquest Corp bought a new stake in Elanco Animal Health during the first quarter worth about $56,000. Covestor Ltd grew its stake in Elanco Animal Health by 510.9% during the first quarter. Covestor Ltd now owns 7,087 shares of the company’s stock worth $74,000 after buying an additional 5,927 shares during the last quarter. MRP Capital Investments LLC grew its stake in Elanco Animal Health by 60.0% during the first quarter. MRP Capital Investments LLC now owns 8,000 shares of the company’s stock worth $84,000 after buying an additional 3,000 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in Elanco Animal Health by 66.6% during the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock worth $92,000 after buying an additional 2,572 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Down 1.5%

Shares of NYSE ELAN opened at $19.77 on Friday. The company’s 50 day simple moving average is $18.35 and its 200 day simple moving average is $14.43. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $21.76. The firm has a market capitalization of $9.82 billion, a P/E ratio of 22.99, a P/E/G ratio of 3.64 and a beta of 1.65. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the business posted $0.30 earnings per share. Elanco Animal Health’s revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of research reports. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. William Blair upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $19.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.